Invivyd, Inc.

Thank you for standing by and welcome to the InVivid 2022 year-end financial results update call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question at that time, please press star 11 on your telephone. As a reminder, today's call is being recorded. I will now turn the conference to the host, Kira Faircloth, Vice President, Advocacy and Corporate Communications.

Please go ahead.

Thank you for joining us today. Before we get started, I want to attend to a few housekeeping items. I invite you to review our press release discussing our full year-ended December 31st, 2022 financial results, which can be found on the investor section of the InVivid website. I would like to remind you that during today's discussion, we will be making several forward-looking statements. Forward-looking statements include statements concerning, among other things, the future of the COVID-19 landscape including the expectation of its continued evolution and emergence of new variants and sub-variants, our ongoing research and clinical development plans, including the timing of these plans, as well as the technology and resources to develop therapeutic or preventative options for COVID-19 and other infectious diseases, our regulatory and commercialization plans and opportunities, and our expected cash runway and other statements that are not historical fact. Forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements, including those described under the heading risk factors in our filings made with the U.S. Securities and Exchange Commission, including our most recent 10-K filed earlier today. It is now my pleasure to introduce the InVivid management team to the call. I am joined by Dave Herring, CEO of InVivid, Dr. Pete Schmidt, Chief Medical Officer, Dr. Lucas Dillinger, Interim Head of Discovery and Preclinical, and Fred Driscoll, Interim Chief Financial Officer. With that, I will turn the call over to Dave.